NASDAQ:GLYC
GlycoMimetics Stock News
$3.00
-0.180 (-5.66%)
At Close: Mar 28, 2024
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
09:51am, Thursday, 21'st Mar 2024
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript
12:24pm, Friday, 03'rd Nov 2023
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
07:00am, Friday, 20'th Oct 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Tuesday, 05'th Sep 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Co
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
07:00am, Wednesday, 19'th Jul 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, Augus
GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy
08:02am, Tuesday, 30'th May 2023
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and techni
GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology
12:20pm, Wednesday, 10'th May 2023
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and the
GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call Transcript
11:09am, Wednesday, 29'th Mar 2023
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chie
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
07:00am, Thursday, 16'th Mar 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on We
GlycoMimetics: Stock Price Drop Brings Great Speculative Trade Opportunity
11:20pm, Wednesday, 08'th Mar 2023
Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should
GLYC Stock: 62.47% Plummet Explanation
05:36am, Thursday, 16'th Feb 2023
The stock price of GlycoMimetics Inc (NASDAQ: GLYC) dropped by 62.47% in the most recent trading session. This is why.
Penny Stocks To Buy After CPI Report? 3 To Watch Today
12:10pm, Tuesday, 14'th Feb 2023
Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?
GlycoMimetics: A Cancer-Cure Lottery Ticket Grabbing My Attention
07:40am, Tuesday, 03'rd Jan 2023
GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial sizes have delivered exceptional results, with the
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
01:16pm, Wednesday, 28'th Dec 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 02'nd Dec 2022
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.